State Budget Crises Force New Restrictions on HIV Drug Assistance Programs

The recent wave of state-level restrictions on AIDS Drug Assistance Programs (ADAPs) marks a significant retreat in the national strategy to end the HIV epidemic. For decades, ADAPs have served as the ultimate safety net for low-income individuals living with HIV, providing life-saving antiretroviral therapy (ART) to those who fall through the cracks of private insurance and Medicaid. However, a confluence of rising drug prices, the expiration of pandemic-era fiscal cushions, and stagnant federal appropriations has forced state health departments to implement drastic cost-containment measures. This shift is particularly concerning as it coincides with a national push to reduce new HIV infections by 90% by 2030, a goal that relies heavily on consistent medication access.

The primary driver of this crisis is the shifting landscape of HIV treatment. While generic oral medications are available, the standard of care has moved toward highly effective, branded single-tablet regimens and, more recently, long-acting injectables. These newer therapies, while improving adherence and patient outcomes, carry significant price tags. For instance, long-acting injectables like Cabenuva require specialized administration and cost significantly more than older oral regimens. When state budgets are drafted, the rapid adoption of these high-cost treatments creates a pharmacy spend that quickly outpaces the fixed block grants provided under Part B of the Ryan White HIV/AIDS Program. This financial pressure is exacerbated by the fact that federal funding for the Ryan White program has not seen a significant inflationary adjustment in several years.

“

This shift is particularly concerning as it coincides with a national push to reduce new HIV infections by 90% by 2030, a goal that relies heavily on consistent medication access.

The methods of limitation vary by state but generally fall into three categories: eligibility tightening, waitlists, and formulary restrictions. Several states have announced plans to lower the income ceiling for program entry. In some jurisdictions, the threshold is dropping from 400% of the Federal Poverty Level (FPL) to as low as 200%, effectively disqualifying thousands of working poor individuals who earn too much for Medicaid but cannot afford the high out-of-pocket costs of HIV specialty drugs. Perhaps more concerning is the return of the waitlist—a phenomenon largely absent since the early 2010s. Waitlists create a dangerous gap in care where newly diagnosed patients or those transitioning between jobs may go months without medication, increasing the risk of viral rebound and community transmission.